Product image of Muvito (Tetracycline Hydrochloride) supplied by GNH India

Muvito

Active Ingredient:
Tetracycline Hydrochloride
Origin:
EU

Muvito (Tetracycline Hydrochloride)

Tetracycline hydrochloride, the active ingredient in Muvito, is a tetracycline‑class antibiotic presented as a topical formulation for cutaneous application. It is used to treat acne vulgaris and a range of bacterial skin infections in patients for whom a prescription‑only therapy is appropriate.

GNH India supplies Muvito as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product delivery across regulated markets, and meeting local regulatory requirements through robust logistics and traceability systems.

Manufacturer / TM Owner

Rafarm Sa.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Muvito (tetracycline hydrochloride) is a topical antibacterial used to manage skin conditions caused by susceptible bacteria.
  • Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the face and trunk.
  • Impetigo: eradicates Staphylococcus aureus and Streptococcus pyogenes causing superficial infection.
  • Folliculitis: decreases bacterial load and associated inflammation of hair follicles.
  • Papulopustular rosacea: helps control secondary bacterial overgrowth contributing to lesions.

How It Works

  • Tetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of aminoacyl‑tRNA to the growing peptide chain. This action halts bacterial growth (bacteriostatic) against a broad spectrum of Gram‑positive and Gram‑negative organisms that are susceptible to tetracyclines.

Side Effects

Muvito may cause local and systemic adverse reactions when applied to the skin.

Common Side Effects

  • Skin irritation or burning sensation at the application site.
  • Pruritus (itching) and mild erythema.
  • Dryness or peeling of the treated skin.
  • Increased photosensitivity to sunlight.
  • Transient discoloration of the skin.
  • Mild contact dermatitis.

Serious or Rare Side Effects

  • Severe allergic reactions such as anaphylaxis.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Extensive bullous dermatitis.
  • Systemic toxicity if absorbed in large amounts.
  • Persistent severe photosensitivity leading to blistering.
  • Rare cases of hepatic or renal impairment.

Precautions & Warnings

  • Before using Muvito, consider the following safety measures.
  • Pregnancy: consult a healthcare professional; safety data are insufficient.
  • Breastfeeding: avoid use unless the prescriber determines benefits outweigh risks.
  • Known hypersensitivity: discontinue immediately if allergic reactions occur.
  • Sun exposure: limit UV exposure and use sunscreen while on therapy.
  • Concurrent topical antibiotics: monitor for increased irritation or resistance.
  • Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Muvito may interact with other medications; awareness of potential interactions is important.

Major Interactions (Avoid)

  • Systemic tetracyclines: concurrent use can lead to additive toxicity.
  • Topical retinoids: increased risk of severe skin irritation.
  • Other photosensitising agents: heightened photosensitivity.

Moderate Interactions (Monitor Closely)

  • Oral contraceptives: possible reduction in efficacy, advise additional contraception.
  • Anticoagulants (e.g., warfarin): monitor INR values for changes.
  • Vitamin D analogues: may increase local irritation; observe skin response.

Frequently Asked Questions

Muvito is a prescription‑only topical formulation containing tetracycline hydrochloride. It is indicated for the treatment of acne vulgaris and various bacterial skin infections such as impetigo, folliculitis, and other conditions where susceptible bacteria are present on the skin.

Tetracycline hydrochloride acts by binding to the bacterial 30S ribosomal subunit, blocking the addition of aminoacyl‑tRNA to the growing peptide chain. This inhibition stops protein synthesis, producing a bacteriostatic effect against a broad range of Gram‑positive and Gram‑negative organisms.

The dosage of Muvito is determined by the prescribing clinician based on the specific condition, severity, and patient factors. The prescriber will provide instructions on the amount to apply, frequency, and duration of therapy.

Safety data for tetracycline hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their healthcare provider before using Muvito.

To order Muvito, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Muvito (tetracycline) offers a broad spectrum of activity against many skin pathogens and provides anti‑inflammatory benefits, which can be advantageous over agents like clindamycin that have a narrower bacterial range. However, tetracycline may cause more photosensitivity, so patient counseling on sun protection is essential.

Muvito should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, direct sunlight, and extreme heat. Ensure the cap is tightly closed to maintain stability.

Muvito is applied topically to the affected skin area. The prescriber will advise applying a thin layer once or twice daily, gently massaging it into the skin until fully absorbed, and avoiding contact with eyes, mucous membranes, or broken skin unless directed.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and extensive bullous dermatitis. Patients should discontinue use and seek immediate medical attention if they develop widespread rash, blistering, or signs of systemic hypersensitivity.

Muvito should not be used by individuals with a known hypersensitivity to tetracycline antibiotics or any component of the formulation. It is also contraindicated in patients who have experienced severe cutaneous adverse reactions to similar agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetracycline Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT